 PRINCETON, N.J., Jan. 6, 2022 PRNewswire -- Soligenix, Inc. Nasdaq: SNGX Soligenix or the Company, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming virtual investor conferences below. 